Today: 29 April 2026
Northern Star Resources (ASX:NST) share price drops 1.7% as $50m Tanami deal closes amid ASX rout
6 February 2026
1 min read

Northern Star Resources (ASX:NST) share price drops 1.7% as $50m Tanami deal closes amid ASX rout

Sydney, Feb 6, 2026, 16:54 AEDT — After-hours.

Northern Star Resources Ltd (NST.AX) shares slipped 1.7% to close at A$26.77 on Friday, with roughly A$182 million changing hands. Rival Evolution Mining (EVN.AX) dropped 1.4%, while Newmont’s ASX-traded depositary interests (NEM.AX) fell sharply by 4.9%.

The drop puts the gold miner on edge heading into Monday, with risk appetite still fragile. Big moves haven’t held, either way, and investors are gearing up for another tough week in commodities and stocks.

MGX Resources (MGX.AX) announced it has finalized the purchase of a 50% stake in the Central Tanami Gold Project joint venture (CTPJV) from Northern Star, handing over A$50 million in cash. CEO Peter Kerr described the deal as “extremely pleased” to close ahead of schedule. MGX plans to collaborate with partner Tanami Gold NL on securing approvals and drafting a development plan. The company also swapped roughly A$5.8 million in bank guarantees and said it will handle the usual post-completion adjustments in due course. nsrltd.com

The market started off under pressure. The S&P/ASX 200 dropped 2% to 8,709, while the All Ordinaries slid 2.2% to 8,955, with miners and banks dragging the indexes lower, ABC reported. Spot gold gained about 1%, hovering near $4,819 an ounce late in the session.

Overnight moves in metals continue to set the pace for gold stocks. Spot gold climbed on Friday but was on track to post a weekly drop, according to Reuters. Silver stayed under pressure, following a sharp decline the day before. “Risk appetite does look diminished … gold is kind of holding its own and silver is caving in,” said Ilya Spivak, head of global macro at Tastylive. Reuters

In that context, the A$50 million inflow came across more as a modest gain than a trigger for rerating. Sellers seemed eager to offload whatever was available, not necessarily what they preferred.

Monday’s open will put to the test if the scramble to de-risk is slowing, especially among miners. With volatility still high, even solid company updates risk getting drowned out on the tape.

There’s a definite risk here. Another drop in precious metals or a fresh shakeup in equities usually drags gold shares down fast — and the rebound, whenever it happens, has been patchy at best.

Northern Star’s FY26 half-year results drop on Feb. 12, marking the next major trigger. Investors will focus on cash flow details and any hints about the firm’s outlook amid ongoing market volatility.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:57 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Caterpillar stock price drops for a second day after a record high — what to watch next for CAT shares
Previous Story

Caterpillar stock price drops for a second day after a record high — what to watch next for CAT shares

Xero share price ends lower as AI disruption fears keep ASX tech under pressure
Next Story

Xero share price ends lower as AI disruption fears keep ASX tech under pressure

Go toTop